Amneal acquires generic manufacturing plant, 18 generic products
PATERSON, N.J. Amneal Pharmaceuticals has completed the acquisition of a liquid-form generic pharmaceuticals manufacturing plant in Branchburg, N.J., as well as gaining the rights to 18 generic products.
This new plant, built in 2004 and equipped with the latest equipment and technology, has a production capacity of 7 million bottles per year of prescription liquids as well as more than 1 billion tablets/capsules per year of oral solids.
Of the 18 products acquired, one is approved, five have been submitted to the Food and Drug Administration, with approvals anticipated in the second quarter of 2008, while 12 products are in the development pipeline to be filed in 2008-09. The first product from this plant will begin shipping in February.
“This addition of an outstanding generic liquid pharmaceuticals manufacturing plant advances Amneal’s strategic plan and enables us to provide a broader offering to our customers. It nicely complements our oral solid capabilities as well as our ophthalmic category joint venture,” said Chirag Patel, Amneal’s president.
Aricept patent is still intact after lawsuit, says Eisai
NEW YORK Even after a decision by a U.S. court related to Japanese Eisai’s Alzheimer’s disease drug, Aricept, the company still insists that its patent is valid.
The U.S. District Court of New Jersey on Dec. 20 dismissed a suit filed by Eisai against Philadelphia-based Mutual Pharmaceutical Co. over the latter’s move to seek Food and Drug Administration approval for marketing a generic version of Aricept. The patent expires in three years.
Eisai Thursday said the ruling was issued on procedural grounds and doesn’t affect the validity of its Aricept patent, which the company believes remains valid through Nov. 25, 2010. Mutual Pharmaceutical still can’t sell a generic version of the drug, Eisai said.
The dismissal, Eisai stated, stemmed from the court’s decision that “there is no case or controversy between the parties, because Mutual did not make a certification challenging the Aricept patent and does not yet have U.S. Food and Drug Administration approval to market its product,” the Wall Street Journal reported.
The Japanese company also said that the U.S. company will give 45 days’ notice of any introduction of a generic version of Aricept.
Eisai this month agreed to pay $3.9 billion to buy MGI Pharma to boost its growth prospects, giving it more reach in the U.S., where Eisai also is building a research-and-development facility.
Bentley to spin off CPEX as independent drug delivery company
EXETER, N.H. Bentley Pharmaceuticals announced Friday that it had filed with the Securities and Exchange Commission to spin off its new subsidiary CPEX Pharmaceuticals as an independent, publicly traded company.
As an independent company, CPEX will focus on drug delivery systems research and marketing. Upon completion of the plan, Bentley will focus on the generics pharmaceutical business, though it will provide CPEX with transitional services, including managerial, operational and administrative support, for a period of up to 24 months.
“Filing the Form 10 with the SEC is an important milestone for the planned spin-off of CPEX,” said James Murphy, chairman and chief executive officer of Bentley. “We are pleased with our progress and believe we are on track to complete the spin-off in a timely manner.”
CPEX drug delivery technology, CPE-215 permeation enhancement, has been validated through commercialization of Testim, a testosterone gel marketed by Auxilium Pharmaceuticals, and is also currently being used to develop Nasulin, an intranasal insulin product.